Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | FDPS | P14324 | 8/20 | 0.45 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27141840 | 1.00 | LMNA (0.65) | LMNAALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL28529788 | 1.00 | LMNA (0.65) | LMNAALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL11797444 | 1.00 | LMNA (0.65) | LMNAALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL19661642 | 1.00 | LMNA (0.65) | LMNAALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL10605396 | 1.00 | LMNA (0.65) | LMNAALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL31243262 | 1.00 | LMNA (0.65) | LMNAALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL9055861 | 1.00 | LMNA (0.65) | LMNAALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL1035585 | 1.00 | LMNA (0.65) | LMNAALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL22814372 | 1.00 | LMNA (0.65) | LMNAALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL27149366 | 1.00 | LMNA (0.65) | LMNAALDH1A1MEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399422-B2 | Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications | POLYPLUS-TRANSFECTION (FR) | 2013-03-19 | — | — | US | disclosed |
| EP-2004156-B1 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | POLYPLUS TRANSFECTION SA (FR) | 2011-01-26 | — | — | EP | disclosed |
| EP-2004156-B1 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | POLYPLUS TRANSFECTION SA (FR) | 2011-01-26 | — | — | EP | disclosed |
| US-20100048672-A1 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | POLYPLUS-TRANSFECTION (FR) | 2010-02-25 | — | — | US | disclosed |
| WO-2008004058-A2 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | POLYPLUS-TRANSFECTION SA (FR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048672-A1 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | C1R, C1S, C3AR1 | LMNA 204/4885ALDH1A1 3574/4885MEN1 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.